Farydak (panobinostat) / Secura Bio  >>  Phase N/A
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Farydak (panobinostat) / Secura Bio
NCT02204553: Expanded Treatment Prot of Panobinostat in Combo w/ Bortez and Dex in Pts w/ Relapsed and/or Refractory Multiple Myeloma

No Longer Available
N/A
US
Panobinostat
Novartis Pharmaceuticals
Multiple Myeloma
 
 
NCT02568943 / 2014-003239-21: An Expanded Treatment Protocol of Panobinostat in Combination Therapy for Relapsed, and Relapsed and Refractory Multiple Myeloma

No Longer Available
N/A
Europe, Canada, RoW
Panobinostat, LBH589
Novartis Pharmaceuticals
Multiple Myeloma
 
 
RECOMM, NCT04150289: A Disease Registry Encompassing the Care Of Patients With Multiple Myeloma on Panobinostat

Completed
N/A
248
US
Farydak
zr Pharma & GmbH
Multiple Myeloma
03/22
03/22
ChiCTR2000040627: Panobinostat Reverses HepaCAM Gene Expression and Suppresses Proliferation by Increasing Histone Acetylation in Urologic neoplasms

Completed
N/A
50
 
No Interventions
Chongqing Medical University; Chongqing Medical University, Natural Science Foundation of China
Urologic neoplasms
 
 

Download Options